Oncocyte (NASDAQ:IMDX – Get Free Report) and 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.
Earnings & Valuation
This table compares Oncocyte and 4D Molecular Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncocyte | $1.67 million | 58.00 | -$50.22 million | ($1.49) | -1.99 |
| 4D Molecular Therapeutics | $92.01 million | 7.15 | -$140.11 million | ($2.63) | -4.52 |
Oncocyte has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Oncocyte has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, indicating that its stock price is 175% more volatile than the S&P 500.
Institutional & Insider Ownership
55.3% of Oncocyte shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Oncocyte and 4D Molecular Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncocyte | -2,955.63% | N/A | -107.52% |
| 4D Molecular Therapeutics | -194.74% | -41.33% | -35.90% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Oncocyte and 4D Molecular Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncocyte | 1 | 0 | 2 | 0 | 2.33 |
| 4D Molecular Therapeutics | 1 | 1 | 10 | 0 | 2.75 |
Oncocyte presently has a consensus price target of $10.50, suggesting a potential upside of 254.73%. 4D Molecular Therapeutics has a consensus price target of $30.22, suggesting a potential upside of 153.97%. Given Oncocyte’s higher probable upside, research analysts plainly believe Oncocyte is more favorable than 4D Molecular Therapeutics.
Summary
4D Molecular Therapeutics beats Oncocyte on 8 of the 14 factors compared between the two stocks.
About Oncocyte
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.
